The New Scientist reports that "two treatments that block a protein called myostatin, which slows muscle growth, are now in the pipeline." You may recall the initial work on muscular mice that pointed the way to the biochemical mechanisms controlling muscle growth. Myostatin therapies have the potential to address age-related muscle loss as well as wasting diseases. "The first approach, announced this week, aims to use a drug to mop up myostatin. Meanwhile a second method, which is already in clinical trials in people with muscular dystrophy, uses antibodies to disable the protein. ... The company hopes to have initial results by late 2006."